Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

iGlarLixi

[Free Whitepaper] 5 Principles for Greater Diversity in Patient Recruitment

Discover how community engagement could enhance diversity in clinical trials patient recruitment

Innovative Trials

- PMLiVE

Innovative Trials attended the Inspire Hertfordshire Award gala dinner

Innovative Trials, a global clinical trial patient recruitment and retention company based in Hertfordshire, has been recognised for its contribution to the county’s economy and business reputation.

Innovative Trials

- PMLiVE

AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants

RSV is the leading cause of hospitalisation for infants aged under one year in the US

Navigating patients step by step on their clinical trial journey

For clinical trial participants, navigating their way through a study can sometimes seem daunting and complicated. Without the right support, around 30% are likely to drop out [1], resulting in...

Innovative Trials

- PMLiVE

Innovative Trials responds to national recommendations to tackle UK clinical trial decline

Kate Shaw, Founder & CEO, comments on the Lord report of the Lord O’Shaughnessy review into commercial clinical trials in the UK.

Innovative Trials

- PMLiVE

Sanofi’s frexalimab shows promise in relapsing forms of MS

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE

Sanofi/Regeneron’s Dupixent shows promise in chronic obstructive pulmonary disease

Approximately 300,000 people in the US live with uncontrolled COPD with evidence of type 2 inflammation

- PMLiVE

Positive results for Sanofi/Regeneron’s Dupixent published in Nature Medicine

The biologic was shown to significantly improve uncontrolled prurigo nodularis symptoms

- PMLiVE

Sanofi signs agreement worth up to $750m for Maze’s Pompe disease drug

The candidate has recently cleared its first phase 1 clinical trial

- PMLiVE

Eli Lilly to sell low blood sugar drug Baqsimi to Amphastar in deal worth over $1bn

The drug is available in 27 markets, with worldwide sales totalling over $139m in 2022

- PMLiVE

New report reveals ‘major’ financial burdens faced by atopic dermatitis patients

The report, commissioned by Sanofi, analyses the economic impact of the condition

- PMLiVE

Novo Nordisk and Aspect Biosystems partner in billion dollar deal for diabetes treatments

The deal to develop a new class of disease-modifying treatments could be worth up to $2.6bn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links